Medscape February 27, 2025
BERLIN — Gut microbial biomarkers identified using machine learning can differentiate patients with inflammatory bowel disease (IBD) from healthy control individuals, according to a study presented at the European Crohn’s and Colitis Organisation (ECCO) 2025 Congress.
Of the four techniques the researchers tested, a “machine learning approach achieves the highest diagnostic accuracy, effectively distinguishing IBD and particularly differentiating Crohn’s disease from healthy controls in independent cohorts,” said study presenter Jee-Won Choi, Department of Biology, Kyung Hee University, Seoul, Republic of Korea.
“Integrating microbial markers with conventional diagnostics could enhance [their] clinical utility,” Choi said. However, further research is needed to determine the long-term validity of the biomarkers, she added.
Some experts questioned the reliability of the markers for IBD diagnosis...
Today's Sponsors
Today's Sponsor